Navigation Links
XBiotech Announces it is Developing Therapy for MRSA
Date:9/4/2013

AUSTIN, Texas, Sept. 4, 2013 /PRNewswire/ -- XBiotech announced today that it has completed discovery and has begun pre-clinical development of a new True Human™ antibody therapy for methicillin resistant staphylococcus aureus (MRSA). The new antibody therapy is expected to be effective at neutralizing drug resistant staphylococcus infection by circumventing key immune evasion strategies of the bacteria, thereby facilitating natural clearance of the bacteria by the patient's own immune system. The Company believes that the therapy could represent a breakthrough in the management of infectious disease. XBiotech reports that the MRSA antibody came out of its True Human™ antibody discovery program for identifying and cloning pharmacologically relevant antibodies from human donors. XBiotech expects this product candidate to enter human clinical trials next year.

One-third of the world's population is believed to have S. aureus bacteria present on or in their bodies (particularly nasal cavities). It is estimated that 2.7% of these cases are MRSA strains which, under certain situations, can cause severe infections such as so called "flesh-eating" disease, necrotizing pneumonia, infective endocarditis, or more commonly impetigo, cellulitis and abscesses. In the US, community acquired MRSA infections have been reported to occur in 25.7/100,000 persons annually, whereas with respect to nosocomial infections, as many as 60% have been reported to be MRSA. Lethal MRSA infections have increased dramatically, killing 30-fold higher numbers of patients in the UK in 2006 compared to just over a decade earlier.

The Company's CEO, John Simard said, "To date, XBiotech has made significant strides on the discovery and development of anti-inflammatory antibodies. We are now truly excited about the possibility of revolutionizing the management of infectious disease through the use of shared natural immunity with True Human™ therapeutic antibodies. Needles to say, we are eager to see this important therapy in the clinic."

ABOUT XBIOTECH
XBiotech is leading the commercialization of biological therapies—including the discovery and development of True Human™ antibodies. The Company's lead product candidate—in Phase III clinical studies—is a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and reduce lead times for biological drugs, ushering in a new era for cost and development efficiency in the biopharmaceutical industry.

Contact: 
Ashley Otero
XBiotech
info@xbiotech.com
512.386.2930


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. XBiotech to Present at UBS Global Healthcare Conference
2. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
3. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
4. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
5. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
6. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against NuVasive, Inc.
7. Hamilton Regional Laboratory Medicine Program Announces Decision to Acquire COPANs WASPLab, the Next Generation Full Laboratory Automation and Digital Bacteriology System
8. IVD Technology Magazine Announces the IVD Business Strategy Conference in San Diego
9. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
10. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
11. Encision Announces Death of Chief Executive Officer Fred F. Perner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 2017 , ... Mediaplanet is proud to announce the launch of its newest ... educate readers on how to take care of all aspects of their skin. , ... melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the disease ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... executives in the life sciences, offering exclusive access to key decision makers who ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Amir Qureshi, MD ... a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has ... are pleased to be the first in Arkansas to introduce the most powerful SCS ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data reveals ... located in the Midwest. With the average cost of healthcare rising and the U.S. ... both the quality and affordability of where they live. An annual 2017 report looked ...
(Date:5/26/2017)... Nevada (PRWEB) , ... May 26, 2017 , ... ... produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed ... conference applications. “We are thrilled to partner with Cupron® to provide customers ...
Breaking Medicine News(10 mins):